Short Survey4th European conference on vaccinology: societal value of vaccination: The impact of Hib conjugate vaccines in preventing invasive H. influenzae diseases in the UK
References (5)
- et al.
Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants [see comments]
Lancet
(1997) - et al.
Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster [see comments]
Lancet
(1997)
There are more references available in the full text version of this article.
Cited by (8)
History of meningococcal vaccines and their serological correlates of protection
2012, VaccineCitation Excerpt :During the last years of the 20th century meningococcal vaccine developments once again drew inspiration from vaccines developed to protect against other bacteria diseases. The success of the Haemophilus influenzae type b (Hib) glycoconjugate vaccine highlighted the advantages of converting polysaccharides into T-dependent antigens by chemical conjugation to carrier proteins [27–29]. Tetanus toxoid, diphtheria toxoid and the non-toxic mutant of diphtheria toxin, CRM197, have been used as carrier proteins for meningococcal vaccines.
The impact of protein-conjugate polysaccharide vaccines: An endgame for meningitis?
2013, Philosophical Transactions of the Royal Society B: Biological SciencesCapture-Recapture Analysis and Pneumococcal Meningitis Estimates in England
2004, Emerging Infectious DiseasesInvasive disease due to nontypeable Haemophilus influenzae among children in Arkansas
2003, Journal of Clinical MicrobiologyProspects offered by genome studies for combating meningococcal disease by vaccination
2001, Pharmacogenomics
Copyright © 1999 Elsevier Science Ltd. All rights reserved.